Last reviewed: June 27, 2026
Last updated: June 27, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Semaglutide works by activating GLP-1 receptors in your brain that regulate hunger and blood sugar, but the timeline for noticing results varies by individual. Most patients report appetite suppression within the first week, though visible weight loss often takes 4–12 weeks depending on baseline metabolism and adherence. Understanding this progression helps set realistic expectations for your weight loss journey.
Week 1–2: When Does Semaglutide Start Working?
During the first two weeks of semaglutide therapy, your body begins responding to the GLP-1 receptor activation at the cellular level. Many patients notice reduced appetite and changes in food cravings within 3–7 days of their first injection, even before measurable weight loss occurs. This initial shift happens because semaglutide slows gastric emptying—the rate food moves through your stomach—and increases satiety signals to your brain.
Early-stage side effects like mild nausea or changes in digestion are common during this window and typically diminish as your system adjusts. You may find that portions that previously satisfied you now feel too large, or that certain high-calorie foods lose their appeal. However, the scale may not reflect these internal changes yet, which is normal and expected at this stage.
Weeks 4–8: When You'll See the Scale Move
The most noticeable weight loss window for semaglutide typically occurs between weeks 4 and 8 of consistent treatment. Clinical trials show that patients often experience 2–4 pounds of weight loss per week during this phase, driven by sustained appetite reduction and increased caloric deficit. By week 8, many patients report that their relationship with food has fundamentally shifted, making adherence to healthy eating patterns feel less like willpower and more like natural preference.
Your dose trajectory also matters during this period—PlexusDx personalizes dosing schedules to optimize your body's response, and your dose may need to go up. Your price won't. As your dose increases gradually, weight loss momentum typically accelerates, though the rate can plateau temporarily between dose increases as your body adapts.
Weeks 12–16: Sustained Progress and Pattern Recognition
Between weeks 12 and 16, semaglutide-induced weight loss often becomes visibly apparent to others around you, and your own clothes begin fitting noticeably looser. Cumulative weight loss by this point typically ranges from 8–15 pounds, depending on your starting weight, baseline metabolism, and consistency with medication and lifestyle changes. At this stage, many patients move into their therapeutic maintenance dose, where weight loss continues at a more gradual but sustainable pace.
Energy levels frequently improve during this window as your body composition shifts and metabolic efficiency increases. You may notice improvements in mobility, sleep quality, and mood—changes not captured by the scale but equally important to your health transformation. Genetic factors identified by the Precision Peptide Genetic Test can help explain why your response curve might differ from the typical timeline, enabling PlexusDx to fine-tune your approach.
Month 4 and Beyond: Plateau Patterns and Long-Term Results
After four months of semaglutide therapy, weight loss typically slows to a more gradual pace of 1–2 pounds per week, which reflects your body reaching a new equilibrium at a lower body weight. Some patients experience brief plateaus lasting 2–3 weeks, which is a normal physiological response and does not indicate treatment failure. Continuing medication through plateaus—rather than stopping—is key, as your body's hunger regulation remains improved even when scale movement temporarily stalls.
Long-term data from semaglutide trials show that patients who maintain their medication continue losing weight through month 12 and beyond, with total weight loss often reaching 15–22% of baseline body weight by one year. PlexusDx's compounded semaglutide injections start at just $149 per month and include access to licensed 503A compounding pharmacies across all 50 states, making sustained therapy affordable and accessible without insurance requirements. Pairing medication with the Precision Peptide Genetic Test ($99 add-on) can reveal which metabolic pathways most influence your response, helping optimize results over the long term.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
How quickly will I lose weight on semaglutide?
Most patients see appetite reduction within days but measurable weight loss between weeks 4–8. Average loss is 2–4 pounds per week in early months, slowing to 1–2 pounds weekly by month 4. Individual timelines vary based on baseline metabolism and consistency with the treatment protocol.
Why doesn't weight loss happen immediately after the first injection?
Semaglutide reduces hunger and gastric emptying right away, but weight loss requires consistent caloric deficit over time. The appetite suppression makes eating less easier, but results on the scale typically appear after 2–4 weeks of sustained reduced intake and increased metabolic adjustment.
Can I start semaglutide with PlexusDx this month?
Yes. PlexusDx offers compounded semaglutide injections starting at $149 per month with no membership fees, insurance requirements, or enrollment delays. Treatment is available across all 50 states through licensed 503A compounding pharmacies, and HSA/FSA accounts are eligible for payment.
Is semaglutide safe for long-term use?
Semaglutide has a strong safety profile across years of clinical use. Common side effects like nausea typically decrease after 1–2 weeks. Serious side effects are rare but include thyroid concerns and pancreatitis symptoms. PlexusDx patients receive medical oversight to monitor tolerability and ensure the medication remains appropriate for your health profile.
How does the Precision Peptide Genetic Test help predict my timeline?
The Precision Peptide Genetic Test ($99 add-on) analyzes 14 metabolic pathways and 49 peptide-related genetic variants, including GLP1R and MC4R function. These insights reveal whether your genetics favor rapid early response or gradual sustained loss, allowing PlexusDx to personalize your dosing and expectations from the start.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
Combining Sermorelin with Zepbound — Benefits and Risks
Does Zepbound Injection Hurt? Understanding the Experience and Techniques